



Date: May 15, 2023

BSE Ltd.,
P J Towers,
Dalal Street,
Mumbai - 400 001.
Scrip Code: 524735

National Stock Exchange of India Ltd.,
Exchange Plaza,
Bandra-Kurla Complex, Bandra,
Mumbai - 400 051.
Symbol: HIKAL

Dear Sir/Madam,

Sub: Press Release - Hikal announces US FDA Audit with Zero Observations

With reference to the subject, we are enclosing a copy of the Press Release titled “**Hikal announces US FDA Audit with Zero Observations**” released by the Company.

This is for your information and records.

Thanking you,

Yours Sincerely,
for **HIKAL LIMITED**

Rajasekhar Reddy
Company Secretary & Compliance Officer

Encl. As above

Hikal Ltd.

Admin. Office: Great Eastern Chambers, 6th Floor, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India. Tel. + 91-22-6277 0299, + 91-22-6866 0300

Regd. Office: 717, Maker Chambers - 5, Nariman Point, Mumbai - 400 021, India. Tel. +91-22 6277 0477. Fax: + 91-22 6277 0500

www.hikal.com info@hikal.com CIN: L24200MH1988PTC048028

Hikal announces US FDA Audit with Zero Observations

Mumbai, 12 May 2023: Hikal announced that the company's pharmaceutical manufacturing facility located at Panoli, Gujarat, was recently inspected by the U.S. Food and Drug Administration (US FDA) in compliance with their requirements. The five-day detailed pre-approval inspection of an API during the period May 8th - 12th, 2023 was concluded with 'Zero 483 observations' from the US FDA Agency.

Sameer Hiremath, Managing Director commented, "As an organization we continue to maintain an excellent track record with global regulatory agencies. This latest audit re-emphasizes our commitment towards maintaining the best in class quality, compliance and regulatory standards across our manufacturing sites."

The Panoli facility was earlier audited twice by the US FDA and successfully approved for manufacturing advanced intermediates and key starting materials. Reflecting on the recent completion of US FDA inspection, Manoj Mehrotra, President – Pharmaceuticals added "Hikal is a leading manufacturer of APIs and Intermediates, and this approval is in line with our diversification strategy which gives us an additional API site to service our global customer base."

About Hikal Limited

Hikal is a reliable long-term partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates, manufactured using stringent global quality standards, for its global customers. Hikal's advanced manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical sectors. The Crop protection facilities are located at Taloja, Mahad (Maharashtra) and Panoli (Gujarat). Hikal's R&T facilities are located at Pune. The Pharmaceutical manufacturing facilities are situated in Jigani (Bengaluru) and Panoli (Gujarat). Hikal is the first Indian life-sciences company to receive the Responsible Care® certification governed by the International Council of Chemical Associations (ICCA).

Investor Relations

Company:	Investor Relations Advisors:	PR Advisors:
Hikal Limited CIN: L24200MH1988PTC048028	Strategic Growth Advisors Pvt. Ltd. CIN: U74140MH2010PTC204285	
Mr. Anish Swadi anish_swadi@hikal.com www.hikal.com	Mr. Jigar Kavaiya jigar.kavaiya@sgapl.net +91 9920602034 www.sgapl.net	Ms. Meeral Salia meeral.s@sgapl.net +91 7738364559 www.sgapl.net

Hikal Ltd.

Admin. Office: Great Eastern Chambers, 6th Floor, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India. Tel. + 91-22-6277 0299, + 91-22-6866 0300

Regd. Office: 717, Maker Chambers - 5, Nariman Point, Mumbai - 400 021, India. Tel. +91-22 6277 0477. Fax: + 91-22 6277 0500

www.hikal.com info@hikal.com CIN: L24200MH1988PTC048028